Bioscience Valuation BSV GmbH

BioScience Valuation (BSV) is a consulting company working at the intersection of life sciences and finance. BSV is a trusted partner for Pharma and Biotech companies and their investors, with a 500+ mandates track record of private and public clients in Europe, the US, and worldwide.
Since 2000, the company has been at the forefront of translating scientific innovation into financial value. Our services cover the entire spectrum of commercial, R&D and financial analyses and deliver unparalleled evidence-based assessments. Based on our profound subject expertise and comprehensive database coverage, our appraisals demonstrate the route to value creation from seed stage to IPO and beyond.
Our strategic alliances enable us to reach out into the US and other markets and to communicate client equity stories within the international investor community.



BSV at a glance:

BSV provides a broad range of services tailored to the specific needs of each client:

Pharmaceutical companies
• Implementation of value-driven R&D portfolio management
• Optimization of R&D productivity, resource/capacity planning
• Forecast of a drug´s sales potential, determination of project value and prioritization in the portfolio context
• Competitive intelligence
• Assessment of in-licensing candidates and potential M&A transactions

Biotech/Medtech companies
• Assessment and valuation of technology platforms, developement products, and the company’s growth potential
• Indication scoping (identification and prioritization of therapeutic indications based on the company’s technology)
• Definition of USP and outline of expected value evolution to create unique equity stories                          • Support of business development and fundraising campaigns
• Negotiation of term sheets and agreements to maximize value

• Opportunity scouting, support of internal due diligence
• Assessment of single assets and entire R&D programs
• Optimization of program/portfolio strategy
• Support of relationship building with US investor community

Strategic alliances
• LaVoie Health Science, USA (Boston, New York)
• FCF Fox Corporate Finance GmbH, Germany (Munich)

Date of Incorporation 2000



Joachim M. Greuel, Ph.D., MBA, Managing Director,
Kerstin M. Bode-Greuel, MD, PhD.
Managing Director,
Address Am Zigeunerbergl 3
82491 Grainau
Telephone/Telefax +49 8821 966 979-10 /-29
Email contact@bioscience-valuation.com
Web Address www.bioscience-valuation.com
Social Media LinkedIn


Beiträge von/mit Bioscience Valuation

„Wir setzen unsere Bewertungsmethoden dynamisch ein“

Plattform Life Sciences: Bitte erläutern Sie uns das Geschäftsmodell der Bioscience Valuation. Bode-Greuel: Bioscience Valuation ist eine global engagierte Boutique-Consultingfirma. Aktuell haben wir acht fest...

Exploiting market inefficiencies in early-stage biotech investing

One dominant hypothesis in finance is the ‘Efficient Market Hypothesis’ (EMH), which states that the stock price of a security reflects all publicly available...

Das Netzwerktreffen der Plattform Life Sciences 2022

Die „Plattform Life Sciences“ hat am 16. November ihre Netzwerkpartner in den Faculty Club G2B (Gateway to Biotech) im Innovations- und Gründerzentrum Biotechnologie (IZB)...

Aktuelle Ausgabe „Biotechnologie 2022“ erschienen!

Unsere Ausgabe 3/22 „Biotechnologie 2022“ ist am Samstag, 24. September, offiziell erschienen. Folgende Schwerpunktthemen möchten wir adressieren: Region Leipzig: Strukturwandel durch Gesundheitswirtschaft Forschung und Entwicklung:...